Sharma East India Hospitals and Medical Research Limited is a public limited company established in **1989**. Headquartered in Jaipur, Rajasthan, the company is a specialized healthcare provider primarily focused on high-quality, low-cost medical services through its flagship facility, **Jaipur Hospital**. While its core competency lies in multi-specialty healthcare, the company also maintains secondary interests in **real estate services**. --- ### **Clinical Specialization & Infrastructure Excellence** The company distinguishes itself through pioneering surgical interventions and a high-standard sterile environment, positioning itself as a premier destination for complex orthopedic procedures in North India. * **Pioneering Surgery:** The company was the first in the state of Rajasthan to perform **Replacement Surgery** using **advanced implants**, establishing a long-standing reputation in orthopedics. * **Sterile Surgical Environment:** The facility features a **State of the Art operation theatre**, which was the first in Rajasthan to implement a **total body exhaust system** and **'Antistatic' flooring** to ensure a totally sterile environment for critical surgeries. * **Quality Benchmarks:** The hospital is accredited by the **National Accreditation Board for Hospitals and Health Care Providers (NABH)**, ensuring adherence to rigorous safety and quality protocols. * **Resource Optimization:** Through a **Related Party Transaction** with **M/s. SG Healthcare**, the company provides medical services on an **Arm's Length Basis** to achieve **full installed capacity utilization** and maximize resource efficiency. --- ### **Institutional Empanelment & Revenue Ecosystem** A significant portion of the company’s patient volume is driven by its extensive network of tie-ups with government bodies, public sector undertakings (PSUs), and private corporations. | Category | Key Empanelled Entities | | :--- | :--- | | **Banking & Finance** | **RBI, SBI, UCO Bank, Bank of India** | | **Government & PSUs** | **North Western Railways (NWR), EPFO, CGHS, ECHS, RIICO, HPCL, JDA, ESIC** | | **Corporate Clients** | **ITC Limited, Hexacom India Limited, Airport Authority of India** | | **Academic & Research** | **University of Rajasthan, Tata Memorial Center Hospital (Tissue Bank)** | | **Insurance (TPAs)** | **Medi Assist, Vipul Medcorp, Paramount Health Services, MD India Healthcare, Raksha TPA, Heritage Health TPA** | --- ### **Strategic Governance & Leadership Continuity** The company is currently modernizing its corporate framework to align with the **Companies Act, 2013**, and ensuring leadership stability to drive long-term growth. * **Executive Leadership:** **Dr. Shailendra Kumar Sharma** has led the company since **1991**. He was recently re-appointed as **Managing Director** for a three-year term (**September 2025 – September 2028**). Notably, he is authorized to receive **professional remuneration as a Medical Practitioner** alongside his managerial salary, ensuring clinical expertise remains at the helm of management. * **Board Refresh (2024-2025):** The board has been strengthened with the appointment of **Mr. Pawan Shorey** and **Mr. Srikant Vinayakrao Bulakh** as **Independent Directors**, and **Mrs. Radhika Sathe** as a **Non-Executive Director**. * **Regulatory Oversight:** **M/s HSPN & Associates LLP** has been appointed as **Secretarial Auditors** for a **5-year term** (FY 2025-26 to FY 2029-30) to ensure sustained compliance. * **Constitutional Updates:** The company has adopted a new set of **Memorandum of Association (MoA)** and **Articles of Association (AoA)** to streamline operations and remove obsolete "Other object clauses." --- ### **Financial Performance & Capital Allocation** The company has demonstrated a consistent upward trajectory in revenue, supported by a strategy of profit reinvestment rather than immediate dividend payouts. **Three-Year Financial Summary:** | Particulars (₹ in Lakhs) | FY 2022-23 | FY 2023-24 | FY 2024-25 | | :--- | :---: | :---: | :---: | | **Gross Income** | 2,078.98 | 2,383.00 | **3,018.59** | | **Profit before Tax (PBT)** | 79.28 | 100.37 | **141.28** | | **Profit after Tax (PAT)** | 83.40 | 66.30 | **124.43** | | **Net Worth** | 1,056.94 | 1,123.24 | **1,247.67** | | **Earnings Per Share (₹)** | 2.96 | 2.02 | **3.79** | * **Capital Reserves:** As of March 31, 2025, the company holds **₹8.32 crore** in 'Other Equity'. The surplus carried to the Balance Sheet rose to **₹831.92 Lakhs** in FY25. * **Investment Capacity:** The Board is authorized to invest, grant loans, or provide guarantees up to **Rs. 100 Crores** under **Section 186**. * **Borrowing Powers:** Limits under **Section 180(1)(c)** have been increased to allow borrowing beyond the aggregate of paid-up capital and free reserves to fund expansion. * **Debt Structure:** The company utilizes **Term Loans** for equipment and an **Overdraft Facility** with **Punjab National Bank** (secured by Jaipur immovable property). Borrowings are typically structured over an **84-month** repayment period. --- ### **Market Dynamics & Operational Risks** While the company occupies a strong niche in Rajasthan, it operates within a challenging economic and competitive landscape. * **Competitive Pressures:** The regional market faces an increasing density of healthcare providers and **price discrimination** within the industry. * **Cost Volatility:** Rising **power tariffs** and the high **capital expenditure** required for modern medical research pose ongoing threats to margins. * **Demographic Constraints:** The target market is characterized by **low per capita healthcare expenditure**, necessitating a high-volume, low-cost operational model. * **Financial Risks:** * **Interest Rate Risk:** Exposure to **Floating Interest Rates** on long-term and short-term borrowings. * **Credit Risk:** Concentration of receivables among **Insurance Companies** and **Government Undertakings**. * **Liquidity Risk:** Managed through **rolling cash flow forecasts** and senior management oversight. --- ### **Critical Regulatory & Compliance Status** Investors should note significant historical and ongoing regulatory challenges that impact the liquidity of the company’s securities. * **BSE Suspension:** Trading of the company’s shares on the **Bombay Stock Exchange (BSE)** is currently **suspended for penal reasons**. While the company has initiated proceedings for the **revocation of suspension**, this remains a pending matter. * **Historical Defaults:** The company previously defaulted on filing **Audited Financial Statements** and **Annual Returns** for **FY 2021-22**. * **Contingent Liabilities:** There is a risk of **fines and penalties** arising from past defaults under the **Income Tax Act**. * **Reporting Standards:** The company has transitioned to **IND-AS compliant** financial reporting to meet current statutory requirements for listed entities.